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Abstract
Background: MELAS syndrome (MIM ID#540000), an acronym for Mitochondrial Encephalopathy, Lactic Acidosis
and Stroke-like episodes, is a genetically heterogeneous mitochondrial disorder with protean manifestations and
occasional kidney involvement. Interest in the latter is rising due to the identification of cases with predominant
kidney involvement and to the hypothesis of a link between mitochondrial DNA and kidney neoplasia.
Case presentation: We report the case of a 41-year-old male with full blown MELAS syndrome, with lactic acidosis
and neurological impairment, affected by the “classic” 3243A > G mutation of mitochondrial DNA, with kidney
cancer. After unilateral nephrectomy, he rapidly developed severe kidney functional impairment, with nephrotic
proteinuria. Analysis of the kidney tissue at a distance from the two tumor lesions, sampled at the time of
nephrectomy was performed in the context of normal blood pressure, recent onset of diabetes and before the
appearance of proteinuria. The morphological examination revealed a widespread interstitial fibrosis with dense
inflammatory infiltrate and tubular atrophy, mostly with thyroidization pattern. Vascular lesions were prominent:
large vessels displayed marked intimal fibrosis and arterioles had hyaline deposits typical of hyaline
arteriolosclerosis. These severe vascular lesions explained the different glomerular alterations including ischemic
and obsolescent glomeruli, as is commonly observed in the so-called “benign” arteriolonephrosclerosis. Some rare
glomeruli showed focal segmental glomerulosclerosis; as the patient subsequently developed nephrotic syndrome,
these lesions suggest that silent ischemic changes may result in the development of focal segmental
glomerulosclerosis secondary to nephron loss.
Conclusions: Nephron loss may trigger glomerular sclerosis, at least in some cases of MELAS-related nephropathy.
Thus the incidence of kidney disease in the “survivors” of MELAS syndrome may increase as the support therapy of
these patients improves.
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Background
MELAS syndrome (MIM ID#540000), an acronym for
Mitochondrial Encephalopathy, Lactic Acidosis and
Stroke-like episodes, is a genetically heterogeneous
mitochondrial disorder with protean manifestations, dif-
ferent expressivity and occasional kidney involvement
[1-5]. The multisystem presentation, variable onset and
severe cerebrovascular involvement are exemplified by
the history of the philosopher and poet Friedrich
Nietzsche who died at the age of 55 after a mysterious
illness. Whether or not the MELAS diagnosis is true,
this historical note has the merit of highlighting the
variable manifestations and clinical mimicry of this rare
disease [6].* Correspondence: gbpiccoli@yahoo.it
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MELAS syndrome is associated in about 80% of cases
with a mutation at position 3243 in the mitochondrial
gene MTTL1 (MIM ID *590050), encoding mitochon-
drial tRNA leucine 1(3243A > G transition), although
other mutations have also been described [7]. Interest in
kidney involvement is rising due to the identification of
MELAS mutations in cases with predominant kidney
involvement, occasionally with very late diagnosis, and to
the description of a putative link between mitochondrial
DNA and different types of kidney neoplasia [8-12].
Kidney involvement is protean, and both glomerular
disease (focal segmental glomerulosclerosis- FSGS) and
tubular lesions, resulting in hyponatremia or in a full-
blown De Toni Fanconi Debré syndrome, have been
described. Furthermore, in several of the reported cases,
kidney involvement was diagnosed only when advanced
renal failure occurred [13-19]. The best-characterized
lesion, leading to kidney biopsy in nephrotic syndrome,
is FSGS. The role of early ischemic changes in the
reduction of the nephron population has not yet been
elucidated [13-19].
We report the case of a patient with MELAS syn-
drome and the “classic” 3243A > G mutation of mito-
chondrial DNA, who developed kidney cancer and
severe and rapid kidney functional impairment after uni-
lateral nephrectomy. Analysis of the kidney tissue at a
distance from the cancer lesion, sampled in an early
phase of kidney disease, in the context of normal blood
pressure, recent onset of diabetes and before the appear-
ance of proteinuria, may allow a better understanding of
the pathogenesis of the renal lesions in MELAS
syndrome.
Case presentation
A 41-year-old male was referred to our Nephrology Unit
because of worsening of kidney function and protei-
nuria. He was born at term of a normal pregnancy from
apparently healthy, nonconsanguineous parents. The
patient’s early development was normal and he had no
evident clinical problem until 18 years of age, when he
developed seizures triggered by light and recurrent
headaches. He was prescribed Valproic Acid and started
a discontinuous follow-up in Neurology. In 1991 (age
22) EEG revealed well-represented alpha background
activity, with a complex wave-peak after 7-10 flashes/
sec, an expression of an epileptogenic photosensitive
centroencephalic focus. In 1992, in the presence of signs
of myopathy (asthenia, increase of serum lactate, myal-
gia), a muscle biopsy showed non-specific changes
(occasional small red sub-sarcolemmal deposits, showing
oxidative enzymatic activity). In 1992 the patient’s sister
(3 years younger) developed generalized seizures and
myopathy. Genetic counseling suggested the presence of
a mitochondrial disease.
Detection of the 3243A > G mutation of mitochon-
drial DNA confirmed the diagnosis of MELAS syndrome
in the patient, his sister, his mother and one of the
mother’s sisters.
In the subsequent decade, he started and discontinued
different types of anticonvulsant therapy (including
Lamotrigine and Phenobarbital), and developed recur-
rent seizures, with imaging evidence of an ischemic
lesion in the left hemisphere, progressive bilateral sen-
sorineural hearing loss and sensitive distal polyneuropa-
thy with increasing muscle weakness. On various
occasions, lactic acidosis was found (lactic acid 10-13.5
mmol/L; normal <2 mmol/L).
In July 2009 (age 39) he was diagnosed with diabetes
mellitus (weight loss, polyuria and polydipsia); at diag-
nosis, glycated hemoglobin was 19.6% and glycemia
<500 mg/dL. Insulin treatment was started. Soon after
diagnosis, he developed a sepsis due to Klebsiella pneu-
moniae. A CT scan, performed on the suspicion of a
pyelonephritis focus, showed a solid hypervascularized
mass, highly suggestive of neoplasia, in the right kidney.
During hospitalization, serum creatinine was 0.9 mg/dL;
24-hour proteinuria was absent at repeated urinalysis;
glomerular filtration rate (eGFR) was 62 mL/min (Cock-
croft and Gault formula). He was normotensive (usual
blood pressure 120/80 mmHg) and remained so during
follow-up.
In November 2009 the patient underwent right
nephrectomy. At surgery, a second small superficial
tumor was detected. The histological examination iden-
tified a renal oncocytoma (2 cm); a smaller lesion (0.5
cm) had an appearance highly suggestive of chromo-
phobe carcinoma. However, the lesion could also repre-
sent a tumoral focus of tubular oncocytosis and a
precursor of another oncocytoma (Figures 1 and 2). The
cytogenetic analysis was not performed, in this case;
however, the two lesions are highly correlated, and a
further definition was considered as of minor clinical
relevance.
At hospital discharge, serum creatinine was 1.17 mg/
dL with mild proteinuria (30 mg/dL). In the same year
the patient’s sister developed breast cancer and was
identified as a carrier of the BRCA-2 mutation. How-
ever, the other family members, including our patient,
preferred not to perform genetic testing for the BRCA
mutation.
In January 2011 the patient was referred to our center.
Glycemic control was good (glycated hemoglobin 6.5%
on Repaglinide). Blood pressure was normal, without
therapy. Cognitive impairment and psychomotor agita-
tion, choreiform movements and intentional tremor,
nystagmus and lower limb muscle weakness, hypotrophy
and severe muscle wasting were present (height 155 cm,
weight 36 Kg, BMI: 15). His speech was slow, slurred
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but coherent, and he appeared severely depressed. His
last biochemical tests were: serum creatinine 2.1 mg/dL
(eGFR 23 mL/min), proteinuria 3.6 g/24 hours, low-nor-
mal total proteins (6.2 g/dL) and normal serum albumin
(3.7 g/dL). EKG was normal; no sign of cardiomyopathy
was detected. Further tests showed: low IgG levels (499
mg/dL), normal IgA and IgM (213 and 115 mg/dL
respectively); high PTH (445 pg/mL); moderate acidosis
(pH 7.227; HCO3 22.8; SBE -3.7; normal lactates: 1.2
mmol/L); antinuclear antibodies and ANCA were
negative.
Renal ultrasounds showed moderate medullary hyper-
echogeneity, consistent with tubulo-interstitial or vascu-
lar damage.
The rapid progression of kidney disease, with the
development of nephrotic proteinuria, led us to review
the samples of kidney tissue at a distance from the can-
cer lesions.
Of note, the changes were recorded before the onset
of proteinuria and in the absence of hypertension, both
at nephrectomy and over the follow-up.
Morphological examination revealed a widespread
interstitial fibrosis and marked vascular changes charac-
terized by intimal fibrosis of arcuate and interlobular
arteries with a wedge-shaped area of interstitial fibrosis
and tubular atrophy extending to the renal capsule sug-
gestive of ischemic damage (Figure 3). Hyaline arteriolo-
sclerosis (Figures 3 and 4) and signs of chronic
inflammation were also seen. These severe vascular
lesions were the basis of the different glomerular altera-
tions including ischemic and obsolescent glomeruli. The
obsolescent glomeruli amounted to approximately 50%
of the more than 100 glomeruli sampled. Some rare glo-
meruli (about 5-10%) showed focal segmental glomeru-
losclerosis, which in this context can be interpreted as
consequent to the vascular alterations.
Figure 1 Renal oncocytoma: the tumor consists of solid, compact nests, acini, tubules or microcysts within a hypocellular hyalinized
stroma. (a). In the box: At high-power magnification the predominant cell type, the so-called oncocyte, is round to polygonal with granular
eosinophilic cytoplasm, round regular nuclei with evenly dispersed chromatin and a centrally placed nucleolus (b) (Hematoxylin eosin stain)
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As the patient subsequently developed nephrotic syn-
drome, these lesions suggest that silent ischemic
changes may result in the development of focal segmen-
tal glomerulosclerosis secondary to nephron loss, at
least in some cases of MELAS-related nephropathy.
Conclusions
The present report regards an adult patient presenting
all the clinical criteria for MELAS syndrome (stroke-like
episodes, with onset before age 40; encephalopathy with
seizures and cognitive impairment; mitochondrial myo-
pathy with lactic acidosis, in the context of normal early
psychomotor development and recurrent headache), as
well as the most frequent complications, namely dia-
betes mellitus (initially defined as type 2 diabetes, but at
present more often defined as mitochondrial diabetes)
and sensorineural hearing loss [1]. Molecular genetic
testing identified the most common mutation found in
MELAS patients, MTTL1 (MIM ID *590050), encoding
mitochondrial tRNA leucine 1(3243A > G transition)
[1,20,21].
The feature of this case is the severity and complexity
of kidney involvement, characterized by kidney cancer
and by severe arteriolonephrosclerosis occurring in the
absence of hypertension, which we speculate may be the
basis for the severe and progressive nephropathy (with
the appearance of nephrotic proteinuria, previously
absent) that developed shortly after nephrectomy (Fig-
ures 1 and 4).
Kidney involvement is reported to be rare and is protean
in MELAS patients [1,20]. Reported cases include: glomer-
ular diseases, mainly FSGS; tubular disorders, either with
Fanconi syndrome or in the form of salt-losing nephropa-
thies; end-stage renal failure [2-4,10-19,21-23]. The
Figure 2 The smaller lesion (0.5 cm): the figure shows a solid growth pattern and perinuclear cytoplasmic clearing. (a). In the box: The
tumor contains a population of large, round to polygonal cells with well-defined cell borders and amphophilic, pale basophilic to foamy
cytoplasm; nuclei are typically hyperchromatic, elongated and grooved with an irregular nuclear membrane. These features suggest
chromophobe renal cell carcinoma; alternatively the lesion may represent a focus of tubular oncocytosis and a precursor of another oncocytoma;
the two types of lesions are in any case strictly correlated [43,44](b) (Hematoxylin eosin stain)
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presence of abnormal mitochondria in tubules and in
podocytes has been described since the first reports, sug-
gesting a direct role of mitochondrial alterations in the
pathogenesis of tubular derangements and of steroid-resis-
tant focal segmental glomerulosclerosis; unfortunately
electron microscopy was not available in our case, thus
impairing any conclusion on the podocyte status in our
patient [12,19]. Most cases of kidney involvement are
described in adolescent and adult patients [2-4,7,8,11-19].
This suggests that kidney disease may develop in the “sur-
vivors” of MELAS syndrome; if this proves to be true, its
incidence may increase as the support therapy improves
[22]. To our knowledge, the role of ischemic changes,
eventually resulting in the development of glomerulo-
sclerosis secondary to nephron loss and nephrotic range
proteinuria, has never been clearly described, also because
these early changes may be greatly underestimated as they
are typically neither symptomatic nor detected by com-
mon laboratory tests until more than 50% of the kidney
parenchyma is damaged.
Our patient was normotensive and non-proteinuric at
the time of nephrectomy, even if his renal function had
probably started to decrease. Indeed, the assessment of
glomerular filtration rate may be a challenge in MELAS
syndrome: none of the commonly employed formulae
for GFR assessment is precise in the presence of muscle
wasting. We chose the Cockcroft and Gault formula as
it takes into account the patient’s weight; however,
neither this nor the MDRD or EPI formulae are reliable
with very low BMI (15 in our patient) and 24-hour
urine studies may be biased by higher creatinine excre-
tion due to myopathy [24].
The kidney tissue analysis showed a severe vascular
nephropathy with ischemic damage affecting glomeruli
despite the absence of hypertension (Figure 3). After
nephrectomy, in parallel with the attainment of very
good diabetes control, he progressively developed
nephrotic proteinuria and kidney functional impairment,
whose kinetics (a few months after nephrectomy) sug-
gested an effect similar to 5/6 nephrectomy [25-27].
Thus, a non-immunologic, non-primarily metabolic but
hemodynamic mechanism of increased work-load on the
remnant nephrons probably contributed to the develop-
ment of FSGS in our patient. Of course, the possibility
of another nephropathy different from FSGS cannot be
completely ruled out, although this is highly unlikely
given the disease course and the genetic background.
Our data do not contrast with the reports of altered
mitochondria in several kidney compartments, being
analogous to what has been described in the brain,
where ischemic lesions coexisted with diffuse cellular
alterations and where swollen and altered mitochondria
were found in different cell types, including neuronal
and endothelial cells [1,12,19,28-30]. The lack of steroid
sensitivity of the nephrotic syndrome in MELAS patients
may be due to the fact that the lesions are caused by
2
1
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Figure 3 Overview of cortical atrophy: the thickness of the renal parenchyma is severely reduced (only 3 mm between the renal
capsule (1) and the arcuate artery (2)). There is widespread interstitial fibrosis, with dense inflammatory infiltrate (3), some tubules are
atrophic with either the classical pattern (4) or with thyroidization type (5), some residual tubules are hypertrophic (6). The arcuate artery shows
a severe narrowing of the lumen by marked intimal fibrosis (PAS stain). In the box: The figure shows the different patterns of glomeruli: normal
(a), ischemic or obsolescent (b), focal segmental glomerulosclerosis (c) (Masson trichromatic stain)
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mitochondrial alterations and by nephron loss of vascu-
lar origin [25-32].
The second interesting aspect of the kidney involve-
ment in our patient is the presence of kidney neoplasia
(Figures 2 and 3). As he refused to undergo further
genetic testing, the role of the BRCA2 mutation could
not be assessed. However, a relationship between kidney
cancer and the BRCA2 mutation has not been reported
thus far. Mitochondrial alterations have been linked to
the development of cancer [33]. While there are some
reports of an association with gallbladder, colon or thyr-
oid cancers, very few reports have linked MELAS syn-
drome and kidney neoplasia; an exception was a clear
renal cell carcinoma in a child, a type of renal cancer
quite unusual in childhood [8,34-36]. Indeed, renal
oncocytomas and chromophobe renal carcinomas, both
derived from intercalated cells of the collecting duct,
display morphological and functional alterations of the
mitochondria [37-40]. A genetic analysis was not per-
formed in our patient to further clarify the diagnosis;
however, cromophobe carcinomas, oncocytomas and
tubular oncocytosis are thought to be pathogenetically
related and further definition of the lesions was not con-
sidered relevant to the case report.
Previous studies have shown that accumulation of
mitochondria in renal oncocytomas is associated with
somatic mutations of mitochondrial DNA, resulting in
decreased activity of the respiratory chain complex [41],
while heteroplasmic mitochondrial DNA mutations are
found in chromophobe renal cell carcinomas [42].
Therefore, it is plausible that the mitochondrial DNA
mutation detected in our patient was responsible for the
development of the closely related cancers [43,44].
Moreover, oncocytoma may be the result of the intrinsic
mitochondrial mutation combined with the tendency for
neoplasms, including oncocytomas, to develop in
chronically diseased kidneys. The occurrence of these
rare and slowly progressive kidney cancers in MELAS
syndrome should be kept in mind in view of the impor-
tance of nephronsparing policies in patients at risk of
1
2
2
Figure 4 Severe impairment of an artery with marked intimal fibrosis leading to narrowing of the lumen. (1). Small arteries (2) have
hyaline deposits (PAS stain)
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end-stage kidney disease because of progressive reduc-
tion of the nephron mass; due to their slow progression,
their prevalence might be underestimated in patients
with MELAS syndrome [37-40].
In conclusion, this case broadens the spectrum of kid-
ney involvement in MELAS syndrome and may clarify
some aspects of its pathogenesis. In particular, it shows
that kidney vascular involvement may precede the devel-
opment of nephrotic range proteinuria, suggesting that
in some patients with MELAS syndrome the glomerular
disease may be linked to the progressive reduction of
the nephron mass. The association with kidney cancer
suggests strict surveillance of MELAS patients for kid-
ney neoplasia, while the rapid progression of kidney dis-
ease after nephrectomy underlines the importance of
nephron-sparing policies in patients in whom renal
function involvement may be “masked” by reduced mus-
cle mass leading to “normal” creatinine values.
Consent
The patient had given informed consent for the genetic
analysis of MELAS syndrome at the time of genetic
counseling. He gave informed consent to the publication
of the present case report and other anonymous reports
on his clinical history. He did not want to perform
further genetic testing for the BRCA2 mutation, as he
was convinced of his poor prognosis for vascular
reasons.
A copy of the written consent is available for review
by the Editor-in-Chief of this journal.
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